C.H.I.P.S. HOME PAGE
MEDICAL CATALOG
TITLE LIST
MANUAL ORDER FORM
ONLINE ORDER FORM
QUESTIONS COMMENTS

Immunology Book from C.H.I.P.S.

Therapeutic Strategies in Lymphoid Malignancies
An Immunotherapeutic Approach
by P. Hilmen

Therapeutic Strategies in Lymphoid Malignancies brings together a series of topical discussions of how the new immunotherapeutic agents can be used successfully to treat lymphoid malignancies.

Features:

  • Concise and up-to-date reviews of the latest clinical developments
  • An international team of contributors drawing on numerous centers of excellence
  • Strategies to select appropriate therapeutic options for individual patients

Contents

  • The history of immunotherapy for lymphoid malignancies
  • Immunologic markers of lymphoid malignancies
  • Diagnostic and prognostic markers of lymphoid malignancies; the latest genetic, cytogenic and haematologic parameters
  • CD20 as a target for immunotherapy
  • Rituximab and chemotherapy: improved response and survival
  • Rituximab and chemotherapy in the elderly
  • The role of rituximab as maintenance therapy for patients with indolent non-Hodgkin's lymphoma
  • Is there a role for interferon-alpha for lymphoid malignancies
  • Radioimmunotherapy safety: radiation protection, administration guidelines, isotope comparisons and quality of life issues
  • Yttrium-90-ibritumomab tiuxetan radioimmunotherapy for low-grade non-Hodgkin's lymphoma
  • Biodistribution of ibritumomab tiuxetan
  • The role of radioimmunotherapy combined with other treatment regimens for non-Hodgkin's lymphoma
  • Tositumomab: new radioimmunotherapy for the treatment of low-grade non-Hodgkin's lymphoma
  • CD52 as a target for immunotherapy
  • The therapeutic role of alemtuzumab in patients with CLL refractory to other treatments
  • Alemtuzumab as first-line treatment for patients with B-cell lymphoproliferative disorders
  • Alemtuzumab in combination with other therapies
  • The role of alemtuzumab (or monoclonal antibodies) in allogeneic stem cell transplantation
  • Alemtuzumab in T-cell malignancies
  • Epratuzumab: A new monoclonal antibody to CD22 in development
  • Patient education

Index

click here to see books videos cd-roms of related interest

ORDER NOW

Therapeutic Strategies in Lymphoid Malignancies
An Immunotherapeutic Approach
by P. Hilmen

2005 256 pages $88.95 + shipping
Texas residents please add 7 % sales tax

Go to Top of Page

copyright © 1997-2006 Culinary and Hospitality Industry Publications Services